Phase 1Terminated
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma
- Sponsor
- Cogent Biosciences, Inc. (Industry)
- Enrollment
- 26 enrolled
- Conditions
- Lymphoma
- Interventions
- ACTR707; rituximab
- Ages
- adults, older adults
- Registry
- NCT03189836
Full record on ClinicalTrials.gov
From the registry
This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and anti-lymphoma activity of an autologous T cell product (ACTR707) in combination with rituximab in subjects with refractory or relapsed CD20+ B cell lymphoma.
Primary outcomes
- Safety as assessed by dose limiting toxicities (DLTs)
- Determination of maximum tolerated dose and proposed recommended Phase 2 dose
History
Last registry update
Primary completion
Started
Registered